Order Now 1-800-246-8878

DiaCarta Webinar Series

Webinar Title: Colorectal Cancer Genetics & A Non-Invasive Test for Colorectal Cancer Mutation Detection Powered by XNA

Time: September 11, 2017, 9:00 – 10:00 a.m. PDT

View Recording


  • Colorectal cancer genetics
  • Driver mutations in a limited number of genes are the ideal candidates for screening & early detection of recurrence
  • ColoScape™: Discuss future use of early identification of subclinical disease, cancer recurrence & monitoring


Sir Walter Bodmer
Title: Head of Laboratory for Cancer and Immunogenetics, Weatherall Institute for Molecular Medicine University of Oxford and Emeritus Professor
Sir Walter Bodmer is the Head of the Cancer and Immunogenetics Laboratory at the Weatherall Institute of Molecular Medicine at the University of Oxford. Research interests of the laboratory include the fundamental genetics and biology of colorectal cancer. Walter Bodmer has held many prestigious appointments including Professor Genetics at Stanford and Oxford Universities, Director of the Imperial Cancer Research Fund (ICRF) and Principal of Hertford College, Oxford. He is a Fellow of the Royal Society, a Foreign Member of the US National Academy of Sciences and was Knighted in 1986 for his contributions to science. In 2013 he was awarded a Royal Society Royal Medal for seminal contributions to population genetics, gene mapping and understanding of the familial genetic disease.

Michael J. Powell, Ph.D.
Title: Chief Scientific Officer, DiaCarta, Inc.
Mike Powell Ph.D. is a highly recognized scientific and business leader with more than 25 year’s experience in R&D, technology, business and corporate development. Dr. Powell has held R&D Director positions at Roche, Microgenics and was a pioneer and lead scientist and inventor of the electrochemiluminescence (ECL) assay technology and also developed catalytic antibodies at IGEN, Inc. which was acquired by Roche for $1.4B in 2003.  Mike has held several other R & D senior management positions at Integrated Genetics Inc., Medisense and Celltech PLC, in the UK. Medisense was acquired by Abbott in 1996 for $876M  and Celltech was acquired by UCB Pharma in 2004 for $1.5B Euro. Mike brings expertise In the fields of molecular diagnostic assay research and development, qPCR and other nucleic acid amplification technologies, and automated instrumentation platforms to DiaCarta.